Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Drug Pricing: Could Expedited Review Of Competing Brands Create The Desired Pressure?

Jul 20 2017

• By Derrick Gingery

US dollars and pills

Related Content

User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases

Jul 13 2017

Priority Review Vouchers Appear To Be Dropping In Price

Jul 27 2016

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow

Aug 01 2016

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Gilead Faces Challenges In HCV, But Competitors Would Switch Places

Feb 12 2016

Gilead Completes HCV Clinical Development With Vosevi Approval

Jul 18 2017

Related Companies

Gilead Sciences, Inc.

AbbVie Inc.

Additional Topics

United States Pricing Debate Generic Drugs Regulation FDA BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.